Skip to main content
SpringerLink
Log in

Der Wandel dominanter Geschäftslogiken durch die Personalisierte Medizin

  • Chapter
  • First Online:
Dienstleistungspotenziale und Geschäftsmodelle in der Personalisierten Medizin

  • 3883 Accesses

Zusammenfassung

Die DNA eines jeden Menschen ist entschlüsselt, dokumentiert in seiner Krankenakte und Grundlage für Behandlungsentscheidungen (Hood und Flores 2012). Medizin wird nicht mehr nur reaktiv praktiziert um zu heilen, sondern auch präventiv, um vorzubeugen (TAB 2008, S. 48). Jeder Mensch übernimmt mehr Verantwortung für seine Gesundheit und nimmt maßgeschneiderte Ernährungspläne und individuelle Therapien mit individualisierten Medikamenten in Anspruch (TAB 2008, S. 47) – das ist die Vision der personalisierten Medizin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  • Amir-Aslani, A. und Mangematin, V. (2010): The future of drug discovery and development: shifting emphasis towards personalized medicine. Technological Forecasting and Social Change, 77(2), S. 203–217.

    Article  Google Scholar 

  • Aspinall, M. und Hamermesh, R. (2007): Realizing the promise of personalized medicine. Harvard Business School Publishing. http://hbr.org/2007/10/realizing-thepromise-of-personalized-medicine/ar/1 (Zugriff am 17.10.2012).

  • Braun, A., Eppinger, E., Kamprath, M. und Wieck, K. (2012): The driving forces of business model innovation: An integrated perspective on personalised medicine.http://dpm.ceip.de/material/ISPIM%20Conference.pdf (Zugriff am 17.102012).

  • Brink, J. und Holmén, M. (2009): Capabilities and radical changes of the business models of new bioscience firms. Creativity and Innovation Management, 18(2): S. 109–120.

    Article  Google Scholar 

  • Chataway, J., Koch, W. und Wu, L. (2012): Public-private collaborations and partnerships in stratified medicine: Making Sense of New Interactions. New Biotechnology,29 (6), S. 732–740.

    Google Scholar 

  • Cheng, S., Koch, W. und Wu, L. (2012): Co-development of a companion diagnostic for targeted cancer therapy. New Biotechnology, 29 (6), S. 682–688.

    Article  Google Scholar 

  • Côté, L., Langley, A. und Pasquero, J. (1999): Acquisition strategy and dominant logic in an engineering firm. Journal of Management Studies, 36 (7). S. 919–952.

    Article  Google Scholar 

  • Dhankhar, A., Evers, M. und Møller, M. (2012): Escaping the sword of Damocles: Toward a new future for pharmaceutical R & D. McKinsey Perspetives on Drug and Device R & D.http://www.mckinsey.com/client_service/pharmaceuticals_and_medical_products (Zugriff am 21.10.2012).

  • Fleck, L.M. (2012): Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices. New Biotechnology 29 (6), S. 757–768.

    Article  Google Scholar 

  • Germino, N. und Chan, K. (2013): Simulation of consumer trends in direct-to-consumer (DTC) genetic testing. Journal of Consumer Health on the Internet, 17 (3) S. 272–28.

    Article  Google Scholar 

  • Gonce, A. und Schrader, U. (2012): Plantopia? A mandate for innovation in pharma manufacturing. McKinsey Quarterly. http://www.mckinseyquarterly.com/files/article/PDF/Plantopia.pdf (Zugriff am 02.11.2012).

  • Hadida, A. und Paris, T. (2013): Managerial control and the value chain in the digital music industry. Technological Forecasting & Social Change,http://dx.doi.org/10.1016/j.techfore.2013.01.005.

    Google Scholar 

  • Harvey, A., Brand, A., Holgate, S., Kristiansen, L., Lehrach, H., Palotie, A. und Prainsack, B. (2012): The future of technologies for personalised medicine. New Biotechnology, 29 (6), S. 625–633.

    Article  Google Scholar 

  • Heitmann, M., zu Knyphausen-Aufseß, D., Mansel, R. und Zaby, A. (2011): Auf der Suche nach Einflussfaktoren auf die Wahl des Geschäftsmodells - Das Beispiel der Biotech-Industrie. Innovative Geschäftsmodelle, Berlin, Heidelberg: Springer, S. 229–248.

    Google Scholar 

  • Hood, L. und Flores, M. (2012): A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory. New Biotechnology, 29 (6), S. 613–624.

    Article  Google Scholar 

  • Kermani, F. und Bonacossa, P. (2003): Current and future prospects for the biotechnology industry. Journal of Commercial Biotechnology, 10 (2), S. 154–161.

    Article  Google Scholar 

  • Konde, V. (2008): Biotechnology business models: An Indian perspective. Journal of Commercial Biotechnology, 15, S. 215–226.

    Article  Google Scholar 

  • Lepoutre, J. und Valente, M. (2012): Fools breaking out: The role of symbolic and material immunity in explaining institutional noncomformity. Academy of Management Journal, 55 (2), S. 285–313.

    Article  Google Scholar 

  • March-Chorda, I. und Yagüe-Perales, R. (2008): New directions for the biopharma industry in Canada: Modeling and empirical findings. Management Decision, 46 (6), S. 880–893.

    Article  Google Scholar 

  • McDougall, G. (2010): Competing in an era of personalised medicine (S.54-56). Drug Discovery, Delivery & Therapeutics. http://www.samedanltd.com/magazine/11/issue/139/article/2751?wt.ac=healthindustries_twitter, (Zugriff am 21.11. 2012).

  • Mittra, J. und Tait, J. (2012): Analyzing stratified medicine business models and value systems: Innovation-Regulation Interactions. New Biotechnology, 29(6), S. 709–719.

    Article  Google Scholar 

  • o.V. McKinsey (2013): Personalized Medicine - the path forward. Pharmaceutical and Medical Products Practice 2013.

    Google Scholar 

  • o.V. PWC(I) (2009): Pharma2020: Challenging business models. Which path will you take? PricewaterhouseCooper’s Health Research Institute.http://www.pwc.com/gx/en/pharma-life-sciences/pharma-2020-business-models/index.jhtml (Zugriff am 14.11.2012).

  • o.V. PWC(II) (2009): The new science of personalized medicine: Translating the promise into practice. PricewaterhouseCooper’s Health Research Institute. http://www.pwc.com/us/en/healthcare/publications/personalized-medicine.jhtml(Zugriff am 04.12.2012).

  • o.V. TAB (2008): Individualisierte Medizin und Gesundheitssystem. Berlin, Büro für Technikfolgenabschätzung beim Deutschen Bundestag.

    Google Scholar 

  • Pickl, M., Ruge, E. und Venturi, M. (2012): Predictive markers in early research and companion diagnostic developments in oncology. New Biotechnology,00(00).

    Google Scholar 

  • Prahalad, C. und Bettis, R. (1986): The dominant logic: A new linkage between diversity and performance. Strategic Management Journal, 7, S. 485–501.

    Google Scholar 

  • Prahalad, C. und Bettis, R. (1995): The dominant logic: Retrospective and extension. Strategic Management Journal, 16, S. 5–14.

    Google Scholar 

  • Prajapati, V., Tripathy, S. und Dureja, H. (2013): Product lifecycle management through patents and regulatory strategies. Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, http://mmj.sagepub.com/content/early/2013/07/17/1745790413497388.

  • Sabatier, V., Craig-Kennard, A. und Mangematin, V. (2012): When technological discontinuities and disruptive business models challenge dominant industry logics: Insights from the drugs industry. Technological Forecasting & Social Change, 79, S. 949–962.

    Article  Google Scholar 

  • Sainz de la Fuente, G. (2013): Personalised medicine, unmet need or business strategy. Journal of Business Chemistry, 10 (1), S. 49–56.

    Google Scholar 

  • Sheibley, P. und Firouzbakht, R. (2009): The era of outcomes: Emerging pharmaceutical business models for high performance. Accenture. http://www.accenture.com/usen/Pages/insight-emerging-pharmaceutical-high-performance.aspx (Zugriff am 20.12.2012).

  • Shore, Parver (2011): The era of outcomes: Emerging pharmaceutical business models for high performance. Accenture. http://www.accenture.com/us-en/Pages/insightemerging-pharmaceutical-high-performance.aspx (Zugriff am 20.12.2012).

  • Styhre, A. (2011): Competing institutional logics in the biopharmaceutical industry: The move away from the small molecules therapies model in the post-genomic era. Creativity and Innovation Management, 20 (4), S. 311–329.

    Article  Google Scholar 

  • von Holleben, M., Pani, M. und Heinemann, A. (2011): Medizinische Biotechnologie in Deutschland 2011, Biopharmazeutika: Wirtschaftsdaten und Nutzen der Personalisierten Medizin. Boston Consulting Group. http://www.vfa-bio.de/vb-de/aktuellethemen/branche/wirtschaftsdaten-und-nutzen-der-personalisierten-medizin.html(Zugriff am 15.11.2012).

  • Zemlo, T. (2004): Pharmacogenomic. Promise, pitfalls. Drug Discovery and Development.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lehrstuhl für Innovationsmanagement und Entrepreneurship, Universität Potsdam, Potsdam, Deutschland

    Karen Smolka & Martin Kamprath

Authors
  1. Karen Smolka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Kamprath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen Smolka .

Editor information

Editors and Affiliations

  1. Universität Potsdam, Potsdam, Germany

    Elisabeth Eppinger

  2. Universität Potsdam, Potsdam, Germany

    Bastian Halecker

  3. Universität Potsdam, Potsdam, Germany

    Katharina Hölzle

  4. Universität Potsdam, Potsdam, Germany

    Martin Kamprath

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Fachmedien Wiesbaden

About this chapter

Cite this chapter

Smolka, K., Kamprath, M. (2015). Der Wandel dominanter Geschäftslogiken durch die Personalisierte Medizin. In: Eppinger, E., Halecker, B., Hölzle, K., Kamprath, M. (eds) Dienstleistungspotenziale und Geschäftsmodelle in der Personalisierten Medizin. Springer Gabler, Wiesbaden. https://doi.org/10.1007/978-3-658-08403-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-658-08403-5_2

  • Published:

  • Publisher Name: Springer Gabler, Wiesbaden

  • Print ISBN: 978-3-658-08402-8

  • Online ISBN: 978-3-658-08403-5

  • eBook Packages: Business and Economics (German Language)

Publish with us

Policies and ethics

Search

Navigation